Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Idera Pharmaceuticals Stock Is Crashing Today


Shares of Idera Pharmaceuticals (NASDAQ: IDRA) were crashing 63.5% at 10:49 a.m. EDT on Friday. The plunge came after the company announced disappointing results Thursday from a late-stage study of tilsotolimod in combination with Bristol Myers Squibb's Yervoy in treating advanced melanoma. 

Idera had hoped that the tilsotolimod-Yervoy combo would sail through its pivotal study. That didn't happen.

The company reported an objective response rate (the percentage of patients with tumor-size reduction of a predefined amount) for patients taking the combo of only 8.8%. Patients receiving Yervoy by itself had an objective response rate of 8.6%.

Continue reading


Source Fool.com

Like: 0
Share

Comments